ࡱ> 57234 bjbj Pccz{;P <<t$$$d$KSF.2"4f"f"f"$'f(lRRRRRRR$UCX*R/$@$//R<<f"f"S:::/Z<Rf"f"R:/R::RP"Qf"Xg=4NRQRS0KSjQmX5mX0QmXQ(|*0:+,C(((RR#8(((KS////mX((((((((( :    June 2015 Table of Contents  TOC \o "1-2" \h \z  HYPERLINK \l "_Toc124828204" Contacts  PAGEREF _Toc124828204 \h 2  HYPERLINK \l "_Toc124828205" FSDLE GUIDE AND INFORMATION  PAGEREF _Toc124828205 \h 3  HYPERLINK \l "_Toc124828206" Purpose of Examination  PAGEREF _Toc124828206 \h 3  HYPERLINK \l "_Toc124828207" Scheduling your FSDLE Exam through ISO Quality Testing, Inc.  PAGEREF _Toc124828207 \h 3  HYPERLINK \l "_Toc124828208" Format of the FSDLE and Fees  PAGEREF _Toc124828208 \h 3  HYPERLINK \l "_Toc124828209" Taking the Examination  PAGEREF _Toc124828209 \h 4  HYPERLINK \l "_Toc124828210" Identification  PAGEREF _Toc124828210 \h 4  HYPERLINK \l "_Toc124828211" Special Accommodations  PAGEREF _Toc124828211 \h 4  HYPERLINK \l "_Toc124828212" Survey  PAGEREF _Toc124828212 \h 4  HYPERLINK \l "_Toc124828213" Exam Results  PAGEREF _Toc124828213 \h 4  HYPERLINK \l "_Toc124828214" Retesting  PAGEREF _Toc124828214 \h 4  HYPERLINK \l "_Toc124828215" How to Use This Study Guide  PAGEREF _Toc124828215 \h 5  HYPERLINK \l "_Toc124828216" Candidate Study Guide  PAGEREF _Toc124828216 \h 6  HYPERLINK \l "_Toc124828217" List of References  PAGEREF _Toc124828217 \h 6  HYPERLINK \l "_Toc124828218" Suggested Supplemental References  PAGEREF _Toc124828218 \h 6  HYPERLINK \l "_Toc124828219" Website Links  PAGEREF _Toc124828219 \h 6  HYPERLINK \l "_Toc124828220" Federal And State Drug Law Exam (FSDLE) Content Outline  PAGEREF _Toc124828220 \h 7  HYPERLINK \l "_Toc124828221" APPENDIX A  PAGEREF _Toc124828221 \h 14  HYPERLINK \l "_Toc124828222" APPENDIX B 18  Contacts All questions about the FSDLE written examinations should be directed to: ISO Quality Testing, Inc. 25400 US Hwy 19 N., Suite 285 Clearwater, FL 33763 Phone: 727-733-1110 Fax: 727-733-5758Questions about licensing should be directed to: Virginia Board of Pharmacy 9960 Mayland Drive, Suite 300 Henrico, VA 23233 Phone: 804-367-4456 Fax: 804-527-4472 FSDLE GUIDE AND INFORMATION This Handbook will provide you with the necessary information regarding scheduling your Virginia Federal and State Drug Law Examination (FSDLE). Purpose of Examination Pharmacists, among all the health professionals, are entrusted with the most important drug control responsibilities. To ensure entry-level competence, the Virginia Board of Pharmacy administers a combined federal and state drug law examination. A single examination tests candidates knowledge of Federal Drug Law and Virginia Pharmacy Law and Regulations. Scheduling your FSDLE Exam through Iso-Quality Testing (IQT) The state of Virginia has contracted with Iso- Quality Testing (IQT) to conduct its examination program. You are now able to register for your FSDLE Exam at any of IQTs locations, via the IQT website www.isoqualitytesting.com. A listing of the IQT test centers can be found by visiting their website or by calling their toll free registration number at: 866-773-1114 between 8 a.m. and 5 p.m. (Eastern Time) Monday through Friday. Appointments are available Monday through Friday at most testing centers with some weekend availabilities. You must schedule your exam at least 5 days prior to your potential exam date. Cancelling or rescheduling your exam: If you fail to show up for your examination at the scheduled time, do not have the proper identification, or do not have your admission document, you will not be allowed to sit for your exam and you will be considered a No-Show, your examination fees will be forfeited, and you will be required to re-register and pay all fees prior to sitting for the exam. However, if an issue arises that prohibits you from making it to your scheduled exam, you may reschedule up to (5) calendar days before your scheduled exam date. At the time of registration you will be asked a series of questions: Full Legal Name Your official name on record given to the Virginia Board of Pharmacy. Social Security number or Virginia DMV control number This is your personal identification number that will be used by both the Virginia Board of Pharmacy and IQT. When The day and time you wish to take your exam. Where The location of the Testing Center. Payment You must pay IQT for the exam with a personal credit card. Should you require other arrangements please contact IQT. All FSDLE data is the property of the Virginia Board of Pharmacy and may not be used for any other purpose than authorized by this order. Format of the FSDLE and Fees The exam consists of 100, multiple-choice questions. It includes several simulations of prescriptions, labels, and refill records. Only one correct response exists for each question. Candidates are given two hours for its completion. A passing score of 75 is required. The fee for this exam is $112 and payable to IQT at the time of registration. Taking the Examination Your examination will be administered via computer at an IQT Testing Center. You should arrive 10 minutes prior to your schedule appointment to allow time for you to sign in, verify your Identification, and allow you to familiarize yourself with the software. You do not need any computer experience or typing skills to take the exam. You have available to you a demo test that will familiarize you with the testing software and its features. The link for the demo test is  HYPERLINK "https://www.iqttesting.com/Default.aspx?Function=SampleExam&Exam=8" https://www.iqttesting.com/Default.aspx?Function=SampleExam&Exam=8. This demo test is available to you any time prior to you taking your exam and you can access it as often as you like. Identification  Prior to test administration you must provide the testing center positive identification. The identification presented must be valid government issued ID and include a current photograph, full legal name as submitted during registration, signature, and social security number or Virginia DMV control number. This information may be presented in more than one form of identification. Acceptable forms of Identification include drivers licenses, government identification cards, passports, alien residency cards, and military identification. Failure to provide appropriate identification at the time of examination will be considered a missed appointment. This will result in forfeiture of exam fees. For additional information on identification and authorization please contact IQT before scheduling your exam. Special Accommodations Should you require special accommodations please contact the Virginia Board of Pharmacy prior to scheduling your exam. Survey At the end of your exam you will be asked a series of questions regarding your overall testing experience. All completed surveys are forwarded to IQT for further evaluation. Exam Results At the end of your exam you will be issued a pass/fail letter. You will then sign out on the daily sign in/out log. If successful in passing, you will receive your license to practice from the Virginia Board of Pharmacy within one week provided all other requirements have been met. It is important to note the pass letter is not considered authorization to begin practicing. Retesting If you fail the exam you may retake it only after a 30-day waiting period. Please visit the website  HYPERLINK "http://www.isoqualitytesting.com" www.isoqualitytesting.com to schedule your retake. You will be required to pay the examination fee of $112 each time the test is administered. How to Use This Study Guide Be sure to obtain all references listed for the examination. The supplemental references listed herein are highly recommended. You should become thoroughly familiar with the study guide. To prepare for the examination the candidate is referred to the behavioral objectives for a description of the exam's content. You should recognize that the list of competencies or behavioral objectives in this guide specifies the title, chapter, and section number of the law and regulations for which test questions exist. Only specified sections within each chapter of the law are tested. While emphasis should be placed on the sections specifically indicated, it is recommended that you master all the relevant law and regulations for full comprehension. The examination covers all state and federal law and regulations required for competent entry-level practice. Since much of state drug law duplicates federal law, emphasis is placed on state law, and where possible, information is referenced to state law rather than to federal law. Specific mention of titles, chapters, and sections of federal drug law is limited to those areas of federal law not already covered within the body of state specific law. It is recommended that you supplement your study of pharmacy law by reading additional text books, journals, and related academic course materials. Recognize that laws, rules, and standards are modified from time to time, and it is your responsibility to keep your knowledge current during the course of your future professional practice. Candidate Study Guide Federal and State Drug Law Exam (FSDLE) List of References 1. Code of Virginia Pharmacy, General Provisions (54.1-3300 through 54.1-3319) 2. Board of Pharmacy Regulations (18 VAC 110-20-10 through 18VAC 110-20-680) 3. Code of Virginia Drug Control Act (54.1-3400 through 54.1-3472) 4. Code of Virginia Crimes Involving Health & Safety (18.2-247 through 18.2-265) (18.2-8 through 18.2-16) 5. Code of Virginia Department of Health Professions General Provisions (54.1-2400 through 54.1-2409)  6. Code of Virginia Department of Health Professions (54.1-2500 through 54.1-2510) 7. Federal Controlled Substance Act (21 USC 801 et seq) (21 CFR 1301 et seq) 8. Federal Food, Drug, and Cosmetic Act (FDCA) (21 USC 301 et seq) 9. Prescription Drug Marketing Act of 1987 (21 USC 353) Suggested Supplemental References Pharmacy Law Digest Facts and Comparisons, Inc. 111 West Port Plaza, Suite 400 St. Louis, MO 63146-3098 800.223.0554 Website Links VIRGINIA BOARD OF PHARMACY:  HYPERLINK "http://www.dhp.virginia.gov/pharmacy" www.dhp.virginia.gov/pharmacy Click on Laws and Regulations UNITED STATES CODE:  HYPERLINK "http://www.gpo.gov/fdsys/browse/collectionUScode.action?collectionCode=USCODE" http://www.gpo.gov/fdsys/browse/collectionUScode.action?collectionCode=USCODE CODE OF FEDERAL REGULATIONS:  HYPERLINK "http://www.gpo.gov/fdsys/browse/collectionCfr.action?collectionCode=CFR" http://www.gpo.gov/fdsys/browse/collectionCfr.action?collectionCode=CFR Federal And State Drug Law Exam (FSDLE) Content Outline I. Licensing, registration, and inspection (24%) A. Obtain, renew, and maintain pharmacist license 1. Describe the requirements and procedures involved in obtaining and renewing a pharmacist license (54.1-3310, 54.1-3311, 54.1-3312, 54.1-3313, 54.1-3314, 18 VAC 110-20-20, 18 VAC 110-20-30, 18 VAC 110-20-40, 18 VAC 110-20-50, 18 VAC 110-20-60, 18 VAC 110-20-70, 18 VAC 110-20-80) 2. Explain the requirements for completing continuing education and maintaining documentation (54.1-3314.1, 18 VAC 110-20-80, 18 VAC 110-20-90, 18 VAC 110-20-100) 3. Explain dispensing activities which are restricted to pharmacists (54.1-3320,18 VAC 110-20-270) Describe registration procedures for obtaining and renewing registration for pharmacy technicians (54.1-3321,18 VAC 110-20-101, 18 VAC 110-20-105, 18 VAC 110-20-106) Explain authorized duties of registered pharmacy technicians (54.1-3321, 18 VAC 110-20-111, 18 VAC 110-20-270) Explain requirements and responsibilities for supervising intern practical experience (54.1-3320 (B), 54.1-3321(C),18 VAC 110-20-40(B)) Explain scope of practice Practice of pharmacy (54.1-3300, 54.1-3408 (I)) Pharmacy intern (54.1-3300) Pharmacy technician (54.1-3300) Supervision, personal supervision(54.1-3300,18 VAC 110-20-10) B. Maintain standards of legal and professional conduct 1. Explain grounds for disciplinary action (a) List the grounds for revocation or suspension of a pharmacist's license or of a pharmacy permit (54.1-3315, 54.1-3316, 54.1-2408.1, 54.1-2409) (b) Recognize requirement to maintain patient confidentiality (32.1-127.1:03) (c) Describe prohibitions regarding patients right to choose and disclosure of kickbacks, fee-splitting (18 VAC 110-20-390) (d) Recognize practice constituting unprofessional conduct (18VAC 110-20-25, 54.1-3316) C. Obtain, renew, and maintain pharmacy permits 1. Explain the requirements and procedures involved in obtaining and renewing a pharmacy permit (54.1-3434, 18 VAC 110-20-20, 18 VAC 110-20-110, 18 VAC 110-20-120) (a) File application to open a new pharmacy, change location of an existing pharmacy, make structural changes to a prescription department, or make changes to a previously approved security system (54.1-3434, 18 VAC-110-20-140) (b) Describe the requirements for display of pharmacy permit (54.1-3430) (c) Describe the responsibilities for the pharmacist in charge (54.1-3432, 54.1-3434, 18 VAC 110-20-110, 18 VAC 110-20-440) Meet physical requirements, restrict access and maintain proper storage and security of all Schedule II-VI controlled substances and devices Explain the requirements for physical standards and minimum required equipment for pharmacies (18 VAC-110-20-150, 18 VAC 110-20-160, 18 VAC-110-20-170) Explain the requirements for enclosures to the prescription department (as defined in regulation) and access to the prescription department both in the presence or absence of a pharmacist (18 VAC 110-20-10, 18 VAC 110-20-190) Explain the requirements for an alarm system and when it should be activated (18 VAC 110-20-180) Explain the requirements for appropriate storage for drugs, devices, controlled substances, controlled paraphernalia, and expired drugs (18-VAC 110-20-200, 54.1-3469) Explain the requirement for drug storage and security outside the pharmacy, throughout hospitals and long term care facilities (18 VAC 110-20-420(A)(1), 18 VAC 110-20-440, 18 VAC 110-20-530 (3-6), 18 VAC 110-20-470) Explain the requirements and documentation for managing after-hours access to the pharmacy in a hospital (18 VAC 110-20-450) Explain the procedures for closing a pharmacy, changing hours of operation, changing ownership, and appropriate disposition of drugs and records (54.1-3434, 54.1-3434.01, 18 VAC 110-20-130, 18 VAC 110-20-135) Explain the requirements for implementing a pharmacy Continuous Quality Improvement program (54.1-3434.03) D. Comply with inspection authority of the Board of Pharmacy and the State Police 1. Describe powers of inspection and inspection procedures and access to records by board agents and state police (54.1-3307, 54.1-3308, 54.1-3405) 2. Describe access to prescription records during inspections (54.1-3405) E. Comply with DEA and FDA requirements 1. Determine the need for and describe the procedures involved in obtaining and renewing DEA registration (21 CFR 1301) 2. Explain the regulations governing discontinuance of practice (21 CFR 1301.52, 21 CFR 1307.21) 3. Explain the requirements for registration modification and transfer (21 CFR 1301.51, 21 CFR 1301.52) 4. Describe powers of inspection, inspection procedures, access to records by DEA and FDA agents, and rights of pharmacists (21 CFR 1316, 21 USC 360(h), 21 USC 374)) 5. Understand the restrictions which are imposed on the hiring of persons having access to Schedule II-V controlled substances (21 CFR 1301.76) Ordering, receiving, and managing drug inventory (20%) Ordering and receiving controlled substances Determine the conditions for legally transferring Schedule II-VI controlled substances between registrants (54.1-3414, 54.1-3415, 54.1-3435.02) Explain the use of official DEA order forms in ordering and transferring Schedule II controlled substances (21 CFR 1305) Explain the conditions under which drugs may be ordered or purchased (18-VAC 110-20-395, 21 USC 353) Explain requirements for maintaining records of receipt for Schedule II-VI controlled substances (54.1-3404(C), 18 VAC 110-20-240(A), 21 CFR 1305.13) Inventory Perform inventory of Schedule II-V controlled substances, and describe the inventory requirements in terms of dates, required records, format, count requirements, filing, and newly scheduled drugs; Perform perpetual inventory of Schedule II controlled substances (54.1-3404 (A and B), 54.1-3434, 18 VAC 110-20-110(D), 18 VAC 110-20-240(A)) Maintain drug integrity Ensure and maintain integrity of drug product Evaluate drugs to determine whether they meet all legal requirements for selling, distributing, or dispensing and recognize the conditions under which drugs are adulterated or misbranded while being held for dispensing (54.1-3461, 54.1-3462) Understand the use and application of the following: Storage temperature (18 VAC 110-20-10) Tight container (18 VAC 110-20-10) Unit dose container (18 VAC 110-20-10) Unit dose package (18 VAC 110-20-10) Unit dose system (18 VAC 110-20-10) Well-closed container (18 VAC 110-20-10) Compliance packaging (18 VAC 110-20-10) Beyond-use date (18 VAC 110-20-10) Expiration date (18 VAC 110-20-10) (c) Explain the conditions under which drugs and devices previously dispensed may be accepted for return to stock for resale (54.1-3411.1, 18 VAC 110-20-400) (d) Repackage and label prescription drugs Explain packaging and labeling requirements to include determination of appropriate expiration date for repackaged drugs (18 VAC 110-20-355(B)) Explain records required for reconstitution, bulk compounding, and repackaged drugs (18 VAC 110-20-355 (A)) Explain requirements for use of automated counting or dispensing devices (18 VAC 110-20-355(C)) D. Provide for proper disposal of drugs 1. Properly dispose of Schedule II through VI controlled substances (54.1-3417, 18 VAC 110-20-210) (a) Identify the procedure for the destruction or disposition of unwanted Schedule II-VI controlled substances (54.1-3417, 18 VAC 110-20-210) (b) Explain record keeping requirements (54.1-3404(D), 18 VAC 110-20-210) Explain the requirements for disposition of discontinued drugs for long term care facilities, to include records (18 VAC 110-20-530(7)(A-D)) E. Report stolen or lost drugs 1. Explain the reporting requirements for theft or loss of Schedule II-V controlled substances (54.1-3404(E), 21 CFR 1301.76)) 2. Explain the conditions under which an inventory needs to be taken following a drug loss (54.1-3404(E)) 3. Describe record keeping requirements for loss of drugs (54.1-3404(E-F)) III. Review prescriptions (30%) A. Receive prescriptions and orders 1. Describe the general requirements for receipt and documentation of oral prescriptions (54.1-3320 (2), 54.1-3410(B), 54.1-3410(D), 54.1-3411, 18 VAC 110-20-290(C), 18 VAC 110-20-420(A)(2), 54.1-3408.01 (C)) 2. Describe conditions under which a prescription may be faxed or electronically transmitted (18 VAC 110-20-280, 18 VAC 110-20-285) (21 CFR 1311) 3. Explain the requirements for transferring prescriptions between pharmacies (18 VAC 110-20-360) (a) Explain the limitation for transferring a prescription for Schedule III-V controlled substances for refill purposes (21 CFR 1306.25) 4. Explain the requirements for obtaining, recording, and maintaining patient information (54.1-3319(D)) 5. Explain the requirements for filling chart orders for outpatients (18VAC110-20-286) B. Review prescriptions and orders Review prescriptions for legality Ensure that prescriptions are written in good faith within the context of a bona fide physician-patient relationship for a medicinal or therapeutic purpose (54.1-3303(A-B), 54.1-3408) Determine whether a prescription is written within a prescriber's authority and scope of practice (54.13303(A-G)) List which health care practitioners have prescriptive authority in Virginia (54.1-3303(A, D, E, F), 54.1-3401, 54.1-3408)) Describe the conditions under which an out-of-state prescription may be filled (54.1-3303(C)) Discuss the limitations upon accepting prescriptions from medical interns or residents and the purpose of the suffix assigned to the intern or resident for prescribing Schedule II-V controlled substances (18 VAC 110-20-510) Describe the method for handling prescriptions that are declined for reasons other than nonavailability of the drug (18 VAC 110-20-270(D)) Identify the schedules of commonly used drugs as listed in Appendix A Explain the criteria used for the general classification of Schedule I-V controlled substances (54.1-3443(A), 21 USC 811(c)) Explain the restrictions on dispensing narcotics for the purpose of maintenance or detoxification (21 CFR 1306.04-5 , 21 CFR 1306.07) Explain the conditions under which a pharmacist may engage in generic substitution (54.1-3408.03, 54.1-3401 (Definition of therapeutically equivalent drug products)) Review prescriptions for required elements Describe the information that must appear on any prescription (54.1-3408.01, 54.1-3409, 54.1-3410) Identify any additional information required for a valid prescription for a Schedule II-V controlled substances (54.1-3408.01(A), 21 CFR 1306.05)) Conduct drug use reviews Describe the requirements for conducting a prospective drug review prior to dispensing (54.1-3319(A)) Describe the requirements for performing monthly reviews of drug therapy for patients in a hospital or long term care facility (18 VAC 110-20-440(B), 18 VAC 110-20-530(9)) C. Explain requirements for central or remote processing of prescriptions (18 VAC 110-20-276, 18 VAC 110-20-515) IV. Dispensing and distribution (25%) A. Dispensing drugs pursuant to a prescription 1. Describe the appropriate terms necessary for lawful dispensing Repackaged drug (18 VAC 110-20-10) Safety closure container (18 VAC 110-20-10) Special packaging (18 VAC 110-20-10) Terminally ill (18 VAC 110-20-10) Compounding (54.13401) Device (54.13401) Dispense (54.13401) Drug (54.13401) Administer (54.13401) Label (54.13401) Labeling (54.13401) Prescription (54.1-3401) Schedule VI device (54.1-3455) Schedule VI (54.1-3455) Controlled substance (54.1-3401) Controlled substance (21 USC 802(6), 21 CFR 290.1)) Drug sample (21 USC 353, 21 CFR 203.3(aa)) Explain the conditions under which prescriptions for Schedule II controlled substances may be filled to include time limitations, conditions for partial filling and the issuance of multiple prescriptions for the same drug (54.1-3410(A)(1-2), 54.1-3411(1), 18 VAC 110-20-290, 18 VAC 110-20-310, 21 CFR 1306.12) Explain the conditions under which prescriptions for Schedule III-V controlled substances may be filled or refilled to include time limitations, restrictions, and requirements for partial filling (54.1-3410(B), 54.1-3411(2), 18 VAC 110-20-320(A,D)) Explain the conditions under which prescriptions for Schedule VI controlled substances may be filled or refilled to include time limitations (54.1-3410(B, C), 54.1-3411(2,3,4) 18 VAC 110-20-320(B,D)) Describe the records required for dispensing, refilling, or partially filling Schedule II-VI controlled substances, and required record keeping (54.1-3404 (D and F), 54.1-3410, 54.1-3411, 54.1-3412, 18 VAC 110-20-240, 18 VAC 110-20-250,18 VAC 110-20-255, 18 VAC 110-20-320)) Explain how to properly package prescriptions (54.1-3426, 54.1-3427, 18 VAC 110-20-340, 18 VAC 110-20-350) Explain how to properly label prescriptions (54.13410(A)(3), 54.13410 (B)(2), 54.1-3463(A), 18 VAC 110-20-330)) Explain caution label requirement for Schedule II-V controlled substances (21 CFR 290.5) Explain requirements for making an offer to counsel and describe the components of counseling (54.1-3319(B-E)) Explain requirements for compounding (54.1-3401, 54.1-3410.2, 18 VAC 110-20-321 ) Dispensing or distributing drugs by other methods Explain unit dose dispensing systems (18 VAC 110-20-420) Explain procedures and required records for dispensing drugs for floor stock, licensed emergency medical services agencies, emergency drug kits, and stat drug boxes (18 VAC 110-20-460, 18 VAC 110-20-500, 18 VAC 110-20-540, 18 VAC 110-20-550, 18 VAC 110-20-560, 18 VAC 110-20-590(B)) 3. Explain procedures and required records for dispensing drugs from automated dispensing devices (54.1-3434.02, 18 VAC 110-20-490, 18 VAC 110-10-555) Explain procedures and required records for the use of robotic pharmacy systems (18VAC110-20-425) Describe the requirements for delivery of dispensed prescriptions (54.1-3420.2, 18 VAC 110-20-275) Explain the conditions under which insulin can be dispensed (54.1-3419) Describe the conditions and documentation for sale of controlled paraphernalia (54.1-3467, 54.1-3468, 54.1-3469) 8. Explain the conditions and documentation for dispensing Schedule V controlled substances without a prescription (54.1-3416) Prescription monitoring program Describe requirements for reporting covered substances (54.1-2519, 54.1-2520, 54.1-2521, 54.1-2522, 18 VAC 76-20-30, 18 VAC 76-20-40) Describe confidentiality of data and disclosure of information (54.1-2523.1, 54.1-2525,18 VAC 76-20-50, 18 VAC 76-20-60) V. Collaborative Practice (1%) A. Understand requirements for participation in collaborative agreements (54.1 -3300.1, 18 VAC 110-40 et.seq.) APPENDIX A The sections of Virginia law listing drugs within the various schedules are confusing and typically include legal or chemical names. For this reason, Appendix A was developed to assist you in studying this portion of the law for the examination. Appendix A is a listing of drug schedules and some generic and brand names of commonly dispensed drugs in each schedule in addition to some common professional suffixes. Drug names or professional suffixes included in the examination, which require or test for this knowledge, will be taken from this list. KEY WORDS Drug Enforcement Administration (DEA) National Drug Code (NDC) Pharmacist-in-Charge (PIC) Prescription Monitoring Program (PMP) PROFESSIONAL SUFFIXES MD- Doctor of MedicineDPM- Doctor of Podiatric MedicineOD- Doctor of OptometryDO- Doctor of Osteopathic MedicineDC- Doctor of ChiropracticDVM- Doctor of Veterinary MedicineDDS- Doctor of Dental SurgeryDMD- Doctor of Dental MedicinePA- Physician AssistantNP or LNP- Nurse PractitionerRN- Registered NurseLPN- Licensed Practical Nurse SCHEDULE I: Schedule I drugs are drugs which have a high potential for abuse, but which have no accepted medical use in treatment in the United Stated or which lack accepted safety for use in treatment even under medical supervision. SCHEDULE II: GENERIC NAMESOME BRAND NAMESmeperidineDemerolmorphine sulfateM.S. Contin, RoxanoloxycodonePercodan, Percocet, Tylox, OxyContinhydromorphoneDilaudidmethadoneDolophinecodeine (as a single drug entity)fentanylSublimazealfentanylAlfentasufentanilSufentaopiumcocainemethylphenidateRitalinamphetamineBiphetaminedextroamphetamineDexedrinephenmetrazinemethamphetamineDesoxynpentobarbital (suppositories are schedule III)Nembutalsecobarbital (suppositories are schedule III)Seconalamobarbital (suppositories are schedule III)AmytalhydrocodoneTussionex, Vicodin, Lorcet Plus, Lortab, Hycodan, Zydone, Anexsia SCHEDULE III: GENERIC NAMESOME BRAND NAMEScodeine in combination with acetaminophenTylenol with codeine #2, #3, #4; Phenaphen with codeine #2, #3, #4 codeine in combination with aspirinEmpirin with codeine #2, #3, #4butabarbitalButisolbutalbital (unless in combination with acetaminophen, then schedule VI)Fiorinal, Fiorinal with codeine thiopental sodiumPentothalbenzphetamineDidrexphendimetrazineBontril, Prelu-2nandroloneAnabolin, Androlone, Deca-Durabolin, Durabolin, Hybolin, NandrobolicstanozololWinstroloxandroloneAnavarDronabinolMarinol SCHEDULE IV: GENERIC NAMESOME BRAND NAMESdiazepamValiumlorazepamAtivanalprazolamXanaxchlordiazepoxideLibriumoxazepamSeraxprazepamCentraxtriazolamHalcionclonazepamKlonopinchlorazepateTranxeneflurazepamDalmanezolpidemAmbientemazepamRestorilphenobarbitalpentazocineTalwinpropoxypheneDarvonphentermineFastin, Ionamin, Adipex-PdiethylproprionTepanil, TenuatefenfluraminePondiminmazindolSanorextramadol hydrochlorideUltram SCHEDULE V: GENERIC NAMESOME BRAND NAMESmost cough syrups containing codeinediphenoxylateLomotil SCHEDULE VI: All prescription drugs and devices which have not been placed in another schedule are in Schedule VI. This includes any drug or device which is not in another schedule, but which is required by federal law to bear on its label one of the following legends: 1. Rx only or Caution: Federal Law Prohibits Dispensing Without Prescription 2. Caution: Federal Law Restricts This Device To Sales By Or Use On The Order Of A Physician 3. Caution: Federal Law Restricts This Drug To Use By Or On The Order Of A Veterinarian Schedule VI also includes any drug not listed in Schedules I - V which because of toxicity, potential for harm, method of use, or collateral measures necessary to its use is not generally recognized among experts as being safe for use except by or under the supervision of a practitioner licensed to prescribe. GENERIC NAMESOME BRAND NAMESdigoxinLanoxinpenicillin v.Penicillin VKbupropion hydrochlorideWellbutrinamoxicillinAmoxilcephalexinKeflex APPENDIX B I U.S. CODE TITLE 21 FOOD AND DRUGS UNITED STATES CODE: http://www.gpo.gov/fdsys/browse/collectionUScode.action?collectionCode=USCODE (Use the Browse feature) CHAPTER 9 FEDERAL FOOD, DRUG AND COSMETIC ACT 321 Definitions, generally 351 Adulterated drugs and devices 352 Misbranded drugs and devices 353 Exemptions and considerations for certain drugs, devices and biological products 353a Pharmacy compounding 360 Registration of producers of drugs or devices 360c Classification of devices intended for human use 374 Inspection CHAPTER 13 DRUG ABUSE PREVENTION AND CONTROL 802 Definitions 811 Authority and criteria for classification of substances 812 Schedules of controlled substances 823 Registration requirements 827 Records and reports of registrants 828 Order forms 829 Prescriptions CODE OF FEDERAL REGULATIONS (CFR) TITLE 21 CFR FOOD AND DRUGS  HYPERLINK "http://www.gpo.gov/fdsys/browse/collectionCfr.action?collectionCode=CFR" http://www.gpo.gov/fdsys/browse/collectionCfr.action?collectionCode=CFR CHAPTER 1 Part 290 Controlled drugs Part 310 New drugs Part 330 Over-the-counter human drugs CHAPTER 2 Part 1301 Registration of manufacturers, distributors and dispensers of controlled substances Part 1302 Labeling and packaging for controlled substances Part 1304 Records and reports of registrants Part 1305 Order forms Part 1306 Prescriptions Part 1307 Miscellaneous Part 1308 Schedules of controlled substances Part 1316 Administrative functions, practices, and procedures THE PHARMACISTS MANUAL (from the United States Drug Enforcement Agency Diversion Control Program)  HYPERLINK "http://www.deadiversion.usdoj.gov/pubs/manuals/pharm2/pharm_content.htm" http://www.deadiversion.usdoj.gov/pubs/manuals/pharm2/pharm_content.htm     PAGE  PAGE 4  PAGE 13 Virginia Board of Pharmacy FEDERAL AND STATE DRUG LAW EXAMINATION HANDBOOK "'();=>RSTUqrst|}~vk\kK\ jXh}UmHnHujh}UmHnHuh}mHnHuh}0JaJ mHnHu,jWh}>*B*UmHnHphuh}mHnHuh}0JmHnHujh}0JUmHnHujh}Uh}5B*CJ aJ phhz{hAh\jh}@OJQJUh}jh}UmHnHu     ($a$();<=U 3 6 vtnnnnnnnn ! {kdW$$Ifl,"" ` t 0644 l` ap $$Ifa$$a$     3 4 5 O P Q R S T «֞擂k֞Z jZh}UmHnHu,jYh}>*B*UmHnHphu jYh}UmHnHuh}mHnHuh}0JaJ mHnHu,jXh}>*B*UmHnHphuh}0JmHnHuh}mHnHujh}0JUmHnHujh}UmHnHuh\mHnHu#T U V W s t u v     - 淪rgP淒,j[h}>*B*UmHnHphuh\mHnHu j[h}UmHnHujh}UmHnHuh}mHnHuh!N0JaJ mHnHuhh0JaJ mHnHuh}0JaJ mHnHu,jZh}>*B*UmHnHphuh}0JmHnHujh}0JUmHnHuh}mHnHu- . / 0 1 2 3 4 5 Q R S T j k l żűōqżűZō,jy]h}>*B*UmHnHphu j\h}UmHnHuh}mHnHuh}0JaJ mHnHu,j\h}>*B*UmHnHphuh}0JmHnHuh}mHnHujh}0JUmHnHuh\mHnHujh}UmHnHu j\h}UmHnHu    0 1 2 3 4 5 6 7 8 T U V W ] ^ _ y żűōqżűZō,jm_h}>*B*UmHnHphu j^h}UmHnHuh}mHnHuh}0JaJ mHnHu,js^h}>*B*UmHnHphuh}0JmHnHuh}mHnHujh}0JUmHnHuh\mHnHujh}UmHnHu j]h}UmHnHu y z { | } ~   żűōqżűZō,jaah}>*B*UmHnHphu j`h}UmHnHuh}mHnHuh}0JaJ mHnHu,jg`h}>*B*UmHnHphuh}0JmHnHuh}mHnHujh}0JUmHnHuh\mHnHujh}UmHnHu j_h}UmHnHu 6   x % S$If !          8 9 : ; V W X r s t u v w x y z żűōqżűZō,jUch}>*B*UmHnHphu jbh}UmHnHuh}mHnHuh}0JaJ mHnHu,j[bh}>*B*UmHnHphuh}0JmHnHuh}mHnHujh}0JUmHnHuh\mHnHujh}UmHnHu jah}UmHnHu     ! " # $ % & ' C D E F g h i żűōqżűZō,jIeh}>*B*UmHnHphu jdh}UmHnHuh}mHnHuh}0JaJ mHnHu,jOdh}>*B*UmHnHphuh}0JmHnHuh}mHnHujh}0JUmHnHuh\mHnHujh}UmHnHu jch}UmHnHu 123MżűōqżűZō,j=gh}>*B*UmHnHphu jfh}UmHnHuh}mHnHuh}0JaJ mHnHu,jCfh}>*B*UmHnHphuh}0JmHnHuh}mHnHujh}0JUmHnHuh\mHnHujh}UmHnHu jeh}UmHnHu MNOPQRSTUqrst~żűōqżűZō,j1ih}>*B*UmHnHphu jhh}UmHnHuh}mHnHuh}0JaJ mHnHu,j7hh}>*B*UmHnHphuh}0JmHnHuh}mHnHujh}0JUmHnHuh\mHnHujh}UmHnHu jgh}UmHnHu+DEbcwFTprs  4;knĿĿĿηΕ΍Ξ{{{r{{h!N5CJ\h5CJ\hr5CJ\hB*phh}5CJ \ h}CJh}5CJ\h}B*CJphh}B*ph hh5 h}5 h!N5h}B*phh}jh}Uh}mHnHu'h\h\0J>*B*mHnHphu,*+Ecx||ssssg|| $$Ifa$gdh $$Ifa$$If{kdi$$Ifl,"" ` t 0644 l` ap !5GHIJKLMNOPQRST$a$QkdIj$$Ifl0,"LL t644 la $$Ifa$Tpqrs~yssq !$a${kdj$$Ifl,"" ` t 0644 l` ap $If} $Ifgd !qkd k$$IflP ` 064 l` ap xy56hi{k$ & F !a$gdp* $ & F !a$ !qkdk$$IflP ` 064 l` ap npz,AKLWv  (56[]!.3Efg>?}vov hp*5CJ hp*CJ\hp*hp*5CJhp*hp*CJ\hp*5CJ\h5h5h50J5CJaJha0J5CJaJha5CJaJh5h55CJaJ h}CJ\ h}CJhh5CJ\h5CJ\h}5CJ\hr5CJ\+9:;oqkdfl$$IflP ` 064 l` ap $If $ !a$$ & F !a$gdp* 9;Hhx{LUt&')8ѷѷ񷮷~uh<5CJ\hmh~0J5CJ\h~h~5CJ\h~5CJ\jh~5CJU\ha5CJ\h}5CJ\h}B*phhah}CJ h}CJhp*h}5CJ\ hp*5CJ hp*CJ\hp*5CJ\ hp*CJ*;qkd m$$IflP ` 064 l` ap $If ! 3 4 r!s!!!!$If !qkdm$$IflP ` 064 l` ap /Q!!!!!!v"}""##.#/#<#>#)$W$Y$r$$$$$$%)%*%X%Y%r%s%u%%%%%%&&),*,I,_,,ܴܴΟ}h}5@B*CJaJphh}B*phh}@CJaJ h}5\hhp*0J5CJ\jhp*5CJU\h}h"5CJ\h}B*ph h}CJhp*5CJ\h<5CJ\h}5CJ\h}5CJ \/!!!u"v"}"}$If !vkdOn$$IflP ` 064 l` ap }"~"".#/#<#}$If !vkdn$$IflP ` 064 l` ap <#=#>#$$$$If !qkdo$$IflP ` 064 l` ap $$$%%%&$If !qkd8p$$IflP ` 064 l` ap & &&V'W' ) )**j+k+*,+,,,zzzzzzzzxx 0*$ !xkdp$$Ifl|5(( ` 064 l` ap ,,-,.,/,0,1,2,3,4,5,6,7,8,9,:,;,<,=,>,?,@,A,B,C,D,E,F,G,H,I,I,_,,,,,,,,,,,sbbb 00*$^`0{kdq$$Ifl\(( ` t 0644 l` ap $If*$$*$a$ ,,,,,,C-T----.c.t... /./O/n//////*080W0X000000000:1<1=11111ǧ~nh'xh0J5@CJaJhh5@CJaJh5@CJaJjh5@CJUaJh}0J5@CJaJ$jSsh}5@CJUaJjh}5@CJUaJh}6@CJaJh}@CJaJh}B*phh}5@CJaJ+,,-@-A-U-g-------- .+.?.^._.a.u....../ 00*$^`0 0*$//6/K/L///////m{kdr$$Ifl\(( ` t 0644 l` ap $If 00*$^`0 ////#0$0%0&0'0(0)0*080$If 0*$ 0*$$ & F 0*$a$ 00*$^`0$ 00*$^`0a$ 8090:0000111M2O22zzzzzzzzzt$If $ 0*$a${kdr$$Ifl,"( ` t 0644 l` ap 111222K2L2M2N2O222222222!?"?EERIiI$L%LLLQ弸~qqbqqSqSqSqh h4@OJQJ^Jh h4OJQJ^JaJh h4OJQJ^Jh h4;OJQJ^JaJh h45;OJQJ^J"h h45;OJQJ^JaJh}B*phh}h}5@CJaJh'xh0J5@CJaJhh5@CJaJh5@CJaJjh5@CJUaJ222224455$6|ll\\\QQ $ & Fa$gd4$8^8`a$gd4$h^h`a$gd4$a$gd4{kdNt$$Ifl,"( ` t 0644 l` ap $66667;7y777p88;999i:M;$0^`0a$gd4$8^8`a$gd4$ `^``a$gd4$ 0^`0a$gd4$ 8^a$gd4 $h^ha$gd4 $ & Fa$gd4 $ & Fa$gd4M;;<<7=>{>"??x@KAA BBBCCC$L^`La$gd4$8^8`a$gd4$^`a$gd4 & Fgd4 & Fgd4 $ & Fa$gd4 $ & Fa$gd4$0^`0a$gd4CQDDEEEE~FF\GGGRIjIIJ $ & Fa$gd4$$$^a$gd4$$$ & F^`a$gd4 $ & Fa$gd4$ & F ^a$gd4 $ & Fa$gd4 $8^8a$gd4$8^8`a$gd4JJJK8K_KKKKK%LLL~MMJNrN$^`a$gd4 $ & Fa$gd4$x^`xa$gd4$x^`xa$gd4$ & F^`a$gd4 $ & Fa$gd4$ & F 8^a$gd4rNNdOO;PZPPCQQQQQR7SS$TTTTU$0^`0a$gd4$a$gd4 $8^8a$gd4 $h^ha$gd4 $ & Fa$gd4$x^`xa$gd4$8^8`a$gd4QQTTRVSVM]t]_^_x____4a.bb dtdd?e $ & Fa$gd4 $ & Fa$gd4$8^8`a$gd4?eef3flfghhh,iij>> 0*$gdWdTkd3v$$Ifl0," t644 layt J 0$*$Ifgd JTkdu$$Ifl0," t644 layt Jppppqqq"q#q.q6qwdd 0Z6$*$Ifgd JRkduv$$Ifx0H$HH$44 xaxytz{$ Z6$*$Ifa$gd J$ Z6$*$Ifa$gd J 0*$gdWd 6q7qHq]q^qhqqHRkd}w$$Ifx0H$HH$44 xaxytz{ 0Z6$*$Ifgd JRkdv$$Ifx0H$HH$44 xaxytz{qqqqqqqHRkdx$$Ifx0H$HH$44 xaxytz{ 0Z6$*$Ifgd JRkdx$$Ifx0H$HH$44 xaxytz{qqqqqqqHRkdy$$Ifx0H$HH$44 xaxytz{ 0Z6$*$Ifgd JRkd y$$Ifx0H$HH$44 xaxytz{qqqrrrrHRkdz$$Ifx0H$HH$44 xaxytz{ 0Z6$*$Ifgd JRkdz$$Ifx0H$HH$44 xaxytz{rr!r"r#r+r,rFRkd{$$Ifx0H$HH$44 xaxytz{ 0Z6$*$Ifgd JTkd'{$$Ifx0H$HH$44 xaxytz{,r-r=rErFrRr^rHRkd|$$Ifx0H$HH$44 xaxytz{ 0Z6$*$Ifgd JRkdA|$$Ifx0H$HH$44 xaxytz{^r_rqr{r|rrrHRkd}$$Ifx0H$HH$44 xaxytz{ 0Z6$*$Ifgd JRkdI}$$Ifx0H$HH$44 xaxytz{rrrrrrrHRkd~$$Ifx0H$HH$44 xaxytz{ 0Z6$*$Ifgd JRkdQ~$$Ifx0H$HH$44 xaxytz{rr sssBsIsHRkd$$Ifx0H$HH$44 xaxytz{ 0Z6$*$Ifgd JRkdY$$Ifx0H$HH$44 xaxytz{IsJsVssssssH>>> 0*$gdWdRkd$$Ifx0H$HH$44 xaxytz{ 0Z6$*$Ifgd JRkda$$Ifx0H$HH$44 xaxytz{JsVssssssssss7t8t|t}tttttuu/u0uQuRuuuuuuuuuuu vvvv0v1vBvCv\v]vlvmv~vvvvvvvvvvvvvvwwww/w0wVwWwxwογίγίhWdhWd@OJQJ^JhA56@OJQJ^JhWd56@OJQJ^Jhz{$h*aJ h}5aJ h}aJ hWd@hWdOJQJhWd5OJQJ^JhWd6OJQJ^JhWdCJOJQJ^JaJhWd56@OJQJ^Jh"h"5OJQJ^Jh"OJQJ^JhWd@OJQJ^JhWd*wwwwwwL? Z($Ifgd"Okd^$$Ifx0H$HH44 xaxyt" 0Z6$*$Ifgd JOkdߐ$$Ifx0H$HH44 xaxyt Jwwwwwwwwj$ Z6$*$Ifa$gd J$ Z6$*$Ifa$gd J 0*$gdWdRkd$$Ifx0H$HH44 xaxyt" Z($Ifgd"wwxxx#x+xLOkd$$Ifx0H$HH44 xaxyt J 0Z6$*$Ifgd JOkd}$$Ifx0H$HH44 xaxyt J+x,x-x.x;xy?yyyyyKzLz{{{Z($5&`#$/Ifgd JgdWd 0*$gdWdOkd{$$Ifx0H$HH44 xaxyt J{{{{zffZ($5&`#$/Ifgd Jkd$$Ifl0,"LL t 6`50644 layt J{{{{zffZ($5&`#$/Ifgd Jkd$$Ifl0,"LL t 6`50644 layt J{{{{zffZ($5&`#$/Ifgd Jkd$$Ifl0,"LL t 6`50644 layt J{{||zffZ($5&`#$/Ifgd Jkd$$Ifl0,"LL t 6`50644 layt J||||zffZ($5&`#$/Ifgd Jkd,$$Ifl0,"LL t 6`50644 layt J|||||)|*|,|N|d||zukui_____ $ 0*$a$ 0*$gdWdgdWdkd$$Ifl0,"LL t 6`50644 layt J |||*+rstuuقڂ-/0wxz{}~¶©¶혒~vrvrvrvrnjnj`jhw0JUh h[e#hlpjhlpUhRjhTec0JaJhTechTecaJ hTecaJjhTecUaJ h}5aJhh0J@aJhh>*@aJ jhh>*@UaJh}5>*@aJhA5>*aJ h}aJh}5>*aJh}5@aJ$||||}D}j}}}~S~g~h~~~~<h}tu 0*$ $ 0*$a$ۀ܀G΁4uvقyz|}gdTec$a$gd7; $ 0*$a$ 0*$Ѓу҃$a$$h$dN3f]ha$ $dN3fh]h&`#$Ѓ҃ճ hTecaJhw5B*CJ`aJ`phhw5B*CJHaJHphhlph h[e#h0JmHnHuhwjhw0JU hw0JgdTec{ 0&P+p,p-p.p1h/R/ =!"#$% 4567; 0&P1h/R!/ =!"#$% P 0....()()))()00&P/ =!"#$% 8$P....()()))() 00P&P/ =!"#$% P0 8$Dp:....()()))() 00P&P/ =!"#$% 8$DpP....()()))() 00P&P/ =!"#$% P0 8$Dp7 0&P1h/R!/ =!"#$% WDdd X0  # Ab~VpԹ^!i1ZVD*nRVpԹ^!i1PNG  IHDRgAMA|Q pHYs&s&u6ҌUIDATx#ɶ٪(PQZl.dM+Qx.LsQZc` '=FՑ{s2ҹٯbTU@jm0ng7W:ݎ"ܠ9K-C&%Kbj *jƜר_K"< F=-wYR=sȀ3`iWqYόl7 I_QO4n?Ls[/W0 }%j*CRбGS%W0rPx8i?͙OoM:ܳ3~f:ڹARFN MЊJ5*EŌ4溿SɖI:0 Mq@6bP"qE]:AUks+$yaEPm,E #**A-_Y )JbY zC+'W0Ia:Pz?/ǟ eǪʃ6B_Ӓ{v<Bg6ZtFKr/]M~KS!E}>F1WO8e@j`ahvIe & # &93vFo }F}L>i  oRK>&{`t ,z$݃0`@GU8}@-KXh+il(6s'#`丌Y NW4+;/|Yi~1IafqO?Dn #M,JȐ!5&a†¸<(C= :~zb`C0Q܂W&?β20CFũg!ҩg0>:c)HqQ9QBB98; ]UOYRE3SKOrY:̰mK"@_5N[`S:BrFy~= uNtfL`Xi0& c!9tE8lmC Z{ 0.Ofa<חl6585* ̨&h]@lB),&M'[lNfx^o ]B͠0kiv Nf8n%AT` MadPv< nOfi/H9g $ C#+S 6c bG  _|buhXZ~VÂɌ<9_ ^iqt4CB SɌ5-:Uiݩb`"#_K10%*4~OcP0%^|rʦ,rls V;0AbJcȿOaxhh=Š-!F fbQiD~3_+ 705-hLh'z6++^XYfDƒ4Zd?e$ʝߑk̸XdDs+ ιEp+ MmiztG3qjl*MݼaC0k <(nf?GF/rjFvv*AM7sάa[2wavm+|ZZ=0GyU*wK;t%/xVsʭ7m& Z_Gs3OaqQ&b[BR6Gܸ(AY6,&hf?u 0&!{pM"C צv-?p1f}@  q=M(tI>^8Mvt%[o`VwMn AC~5wDnd~(/C,<ëEð3T~&{XNAx q8#a2^Gy٤Axfks/8Ϣ.61- bݘ慮 ӷU4^1ܹgی-Iq[Ƶ > pF⚁]l=R$RHX c([hCh[&BfTŠQvuviwMJӁ; }{2o6L`MkhFB@axpw3Ibdpԑ2@G>Z +x 7yr;}a\HЁb*OF2%ʅBaW i 60m NMI+q rnUR#n֌1|1#hļ1&qfȰ^gb\`018ږqmJi C#7 *~AtJUD# +ܸf)~< } ; dXa^$I46cfd(v,00Pz͐GҦ=]R3A h텾p*fBv֓lW%5V7iBfd lGuEÉ=bH b} [ [5cB1L N :R֎e0ȣ'# _a;JK杌%PBRyC w/6t 2NF-HhuL:9Zҕ2< /Nܤ mfq Ԍ=W9e3*7K nS({Eɡ;!l'C8=F`M&M2G[¤ $Z˅&`jkgb]elW9MSؚrs`m] R.qt`S!_oF]K%[kPͰv!=Fhps |qzK`*StL;8ȫehKLdTwVRӃ ΁dP!-O6[t0J?̪d|D}ѳncCRkS q %b!㎰>fБ/[(PcVQ *> QI{8}2dE'#w>Jt2dpoYtڌ6v`|c!-^ XXm1G#q͘ &)gX%0$8n-a%ReftJxвlA#0ar8`3V˶j1EPT1!ꂼn{,;6`UIuB8zt}FEPl30.OfjYf3q_f>FAFI'h1#1-[%8B؉w,Ngd8~~~jƃ[WAĵ?cGӉ%*h kjn3Z/K-[ nW`p4mKqRD0܆>!4X`(}p* *aTl98.",nRaIK7 \߃2j!7p6~pa#aq8!x.oqnC7)w(7cЄ'cQ5a`FjԳ]kiA[T7?0J_3;_g #@u%1-x7 tFy'#0foFn  ;ÿWիtWhpX)oL;)}:Śa3q ؈ zje`.' 1q:zt- %(l2O5CgЇc2Jb,CP{y|v}*jFˠQ\5#ucUƢ5S] +,=F,2LB֌0 Cd䘹&FtdZÜgqyQ1 nHG4\}gV)q#w>5std1u1@TWeM`e `,{6W7AL܇j(UH}``C -de k`n9B [j|=юi6ڨNFb#!p -G6 0#tuQVB@nj/"b^Fn`,pM8cБfHdl 0;+N>kyob,Sb\7`$f@X"cxLWODX3};L~Ѻf/iFjC3=&w1^KZEvN`Y7Ɨ?Ϊ d 7I7|fKqḫ$L.GMn{dY׌=CJu0<0zOUˉ~* )wG%,tc\2J0T v.~0`4ӫ[dP}b1ظa+?^b.0<_$.t240@_:d m0a208cL kFgL#o.cdž)/#OĨ00%2TC7(ZnӱNg=nïև)aX;5a|3c-8Yb@1yímpxfxv?Af= |q1]1r_bqu2*<ǵaaXϚ2zc f$+u׳xBF_q13= m7`R' \0yao 5K`Sm3|@&} hr#,ƏonaHyj{)`]hx &a Xo{3>"2|/cH`d[ =G#&z.VXz,(ߺ6dC`cW΁ȸc]& Je:N+c 36cazt, {<[pUBgƳgrWx0"c̎0$g\6CĿ>R3$aBoG e=L~ƽ5[&:ĚQcn=-cp82V+,+=2q.Cg,##Q̱dnQC|e:J''0P; (>'0eqFF˸Mh1VE/CX> '.i3FXuvqr>FY]Vn3: vCPxL,֛kav;~dv~ ]ͨdlS?m>a!/t>ff.Abu$\)t{b$ye02jg5"c:l1i,W?Bi3*d G:pKܣwٲi氌}|OTOES,)YCEƊxg a bO`15Ϥ )8aDWzMdT5Cc*Xgap1bcHbbW(Ǩ>O&6^u͘ϯ^42; X3 ,g)Bm#K# -(U/#Os9˷S<ӎA`mO^*OpضW(c#ɲRE_Z촣;ƀb`E-0^GlUvla|ԬBƛ޾2-{ߨ O뚻?vD;`$mƏ ]*\5 6ק0Lsa2bxJBWkn&3,2>aF {Cmƪ<VC9x[m#w1Uv@nyaӟ1Ok0Z f˿2Pkd\lxt,Z}ߗK/ 90@e|SbfL!K"5!cbz+b,z,܀ eׅq '"N pp@^F S%&H /-C3tNտ dVź}q!W(>3A|x 񵚿`;^%̾mFin`Xb|#2ZUga׌Y'12^1.gnET.uc&bR`i# yUCtFƳìq.-F6Ģ(%\%JN0]}ߊO \'ܜ?%NS=0މm1N)BD^I魃28o3T{8 2*Y) ]ح[ YJ0RiFiӹ'Y-C$77mW+Y?oYq~A%ϐa0Eb*>m^T/÷hț^I۾+CS3EFa+ o>` ٔnFaTeu6c1Vse`I)d`$-+?0B+}t(%?Qx5'Ƈz>vH v?!cul"-+5?cUd8pʤxqLu71[3P >/Oނh#A& Bi`RJpSq=JlGP]4c&Lï+Yq(,]&ӏDJ{x'j >TO;T_A V_c,em &O̰a_} en?cHl(ڌY3/% J0zh (k|@ԳU.-Vv2 k.0YǑo[~t! z = y!^ی~5<'~DOTL֯mM8/.ԯga`8#,Y#˱Ў %z4  BC<˷JL=d5L9`]0g%2>6 W,}b` LA Wc~3,c^a)6efX1n1F4a<K`-]:c0ڌ 2?2 &Ԛѿ>0FaD`^gLt2Ox8::1xqf, d|x:aRMv26C<ͰL.7լ!ϩ [S4fxt1f!4yC#:OBO1Rmx11uSGnrmSn1= qO&7 8t.t0]Y}x*{wxZ{چ!2s-{R bfU5sc׸Jx~fyik zb2xi{Q ["y19훸D4̿i0]f%{) ~# uCy5,m14%ȷwOp ~s/+fNڻ+|۷q1sev^39Kw~f`mX|5~o3T{z-xrBaZkU=#wAKQ:U]XggNy\GFMfxPҡkI^?*WA[Qn12xsq١˳_U$|>䆙 7Z ܀̏UȚwD.o807y)~br7|+]n!^*B+Ú!UZ~l3* nɇ_/*傮׌K' 9JQLk%ijj-@.SnbeXpR z 2V'1@)}XS,҄X.k10 0|} "5wi1P3nJҰ_ֿ||9( s;+[ v0r'`B,xX0\E,Ʌv &^ qO9Z`u>m3L($>gT^e*(,+/m6{1]INh /OFɘ̥֗նzrYiw?4tf^mٔ&i3e>յf,.28[Qb1Yso12S6@jF|bȶ-fb}7“bE%00aAj7Gb9}G6_]RaAѫk$0DXkFc(-7V9Q[ƪ-Yw*,z0[&xaH }J0] x\alէ$aON@+6[}9s< cX̀cu` mGck>|<(^4F=PPpe~4H2c{Lc< cMTxcfl2IG.=YGX3=mv;`ʦpmX1t #2Ȁx_̎1jP!ifH(XG) ԏ8 2Z3}6\32b-?7ŊkFgzbEIJ zpyKڴ).r 1 忩{Zt}kRKP0%Uň\{0\2nͨwwAB0&k<1|ZDž(}9Ռrp [00 $ 62h(7(hA=g-Fؔf08107="bѦ@R9 uq"Z&m(֌O8C2go}bp*VjQcKX3%E.Rzә ,K7CEQ X1B}y` !^6a3X3>ugǮMjFIͽ IC ʘs{RQ7W [vU" 0T7J_~>X,kzï "\m^'w[zۅ艘FWﮊ lLsq\Uo{rw"ځNRY~n5ٕ ; ^%(Hq yVW(^0[BCmkG<_h%029^1ûAGhnZs?CdSٳK#HbБ9C Lù6Rv٧٦%MUX5FP1:[P{?A_fk3`p9qU{?Te`L%bi$ՒeXZ4E1YjbXXGX0"vkf`(2cBޜu .1>+@hݺڊ[*aHwop (`XD){kTmq9JCVip9߃.0f1.k{c/|g!l'ΰP /|ȂCMC ) vqKJ/ L6ͬT3<]IRjape#쌙 `/Z;f"4)W:ίOW5ðD%O"$6[lnXw'rqT#yn|@c+o+Kp '+0U5T0kpv0Q`eɧ0[QΚ[ F,Pwe99jDm Ln{4gZΜXΛ_$I 0Q[ψİ3`2q<,J Lrx&'C SEX1 0t&YnBc&=:6i.2xR|4l3bd%9e_0JL8DA*rayp8؀"!moY)nע2̟c1њlܷz'-T_Lo-F t #5&}Z{ ױJ7SŇ+UddFZ5 $;x4.[?io/̗x0*B'VٚQW ][(4 -]ӢںR{c%a%(H(+Šx*V\ s`Gp db6e 0<7J]a`]Ym,iPsfiŲW3C X*T;m2K:ziA9f&EKx,YRg8Tx @!#F N )BOֱ]ViE]3qa <|g yVu0TAXqLgä:@EmdD) m28ۮxŘ{gwf-Cm\VO]d[) D/34 XukQTxJ*,x;}4hR58h0lvaf]@;m1ʀq̸RRr=@ᲘLvN\0lR]ePedpA$ʓxygkax,P_v2{?rWUM$ w 'hN>'0lh3n2T3)࿄K, 2x7C;H 3y3E 084QI{ΝFn1jϸM3,˚<D[:8۲Q&DjVx1Cf%0|CRcd#fOc}Yb,&y߫/V x0`3Ƞ=q|F{a$Ι*@οͺKڗKA%́f] [Hb=@(1~kY3ucbfM#teo5#Q1$0zt}0ө7OaVqd\Z͝8UJ= Vܯsdx-A`U5yZjhFYqpX{XΧVe'Psi`f7⋩PVe|yd$;yl;rWhr{=(RG͸Wn^ːgfo14clEP0caT(@v.fpcN#2\rPez.#fGsA*U :X;n[iuD:n$->&:XAcPl۩UL^X3ט }~!:2q/b.JR'% SmTLF~1¦ztɒ܍~yZ6b~VNR^D`elz >c PjGr mS^] =O4# ^~.IM\3,gwDcݹVxj;n0@H#050wPߏ{!o4|gXI(܄]uA 4Th=-7M Ӏ;Ҽu2Ǹ쮿y'_*s`nٕf ghs+&cψo؛v9Hc 0RrCv k=؍ 1Gr)c#ewy&Fob5qZʡDKQy)yd58KOQjP~I}2hEO㈓rt2 Ӻ X{ی) PʏB'Z*QC+&*ꪏsb8pҢ~[1sY|g)Xq:›je0x&Ud h+b xYB-0_9^8>dQvf ޖ䓹͉o\*.T(dJ4>\clX(8̈́Ec愕0fA%Od U;d>c{- %: WΑ1K('?Lh׮Lţ)rxoei i{ ذZ?ib`bX5'yuwdNDă7ax,ywm:T&ǔ܍ ^04M̂oɓ=0l=r Wvz,u4nǸO;,g7j89>2 B5J{O<Rv?SD{]dS3Y~Eơ{1nBbs̟,,O-uF'A{[J g<oԾu_ ^ɃS *W1:G"N[dsY?!!nW*k17a#bŨx8`ѹ8OqAfz Q%@'hbYʳdPdN/=E<7Jq+Զ$M5#uqVD ͧ)6qwgnpmHDؗ"S8(_,p:(ၥ0wϧRfr49؇|M2<|H ~G]YrNN: О')CxRnR*E!Kc0ɀjIڍ)vm߮hlQEֶfNb_0ށ+ ^ej+3:Lc]N̜yAץxD2ʒ%1k910@ͼ2#*$>`1N p$ƪ8,:BV-D6Gls<6-1]*yipADn09ƪslD0񠂵^TqKE.b`,~WN,n c-yFAb7MS/.guڽ&Ǥ%TzB[^&˘fw^"ŀ{NZ7쌚TXkKt3h_3e녏E?$ +pכTӪ*/~4i 2wޮJ7H4C0,.#oR&O4Fv"W¢FoMuX)J,%iBUx.0XEgOQp“?@9JiQS` %Iz0yL}ĤY]&t !G:2aalF*DߨKzfI>k,1xg3B00$i I9SFCð* =F% IJSV &Ud\\xvОs!sTcr[\O~rʭ>oLG7Wa'*Us Zf΢1dEcŪ\B'}l"P {U2;(*bF9v)ɡcG}ˀ9z6f$f1OL0tPj^:ǀ@)hPf0|B]<0!" ={5k=U_гXewpPC< Nޡ2y$AS{1@-p1-ZEv]p3*b}q!O=gT;%:#/jw80 0/.l,trxA6/eJ,h9 \gClqZo^$'z^PNrEOڷI($FfKlc:c@#oyB i(X^3,r1mtT3k)i*UíqsR]Ш &R*ǠyR"%}廮M?a(t+Σ RW2msU/g`l2>牧w8Ì,J.a:o1:ӽ Tv wo:XF:nQG8Ò0VYjv8OH*x3(22#0Rc@!Yc^sGp.iNOFۓGF/}b%%qvqO3wtV 4\l؀ fYu#JAo6U~K't) rMfq&U8t27Mؘ> `H%ח1z>>+vov`Wu3xɟAgHi5G'}SY+ԟZp$ؐ dO /.@; JFs3jV-S2bYHڌydNTV'Hd ;>Q\wԩYhYM/efͱE0?1YЖvHeIENDB`$$If!vh#v":V l ` t 065"` p }DyK _Toc124828204}DyK _Toc124828204}DyK _Toc124828205}DyK _Toc124828205}DyK _Toc124828206}DyK _Toc124828206}DyK _Toc124828207}DyK _Toc124828207}DyK _Toc124828208}DyK _Toc124828208}DyK _Toc124828209}DyK _Toc124828209}DyK _Toc124828210}DyK _Toc124828210}DyK _Toc124828211}DyK _Toc124828211}DyK _Toc124828212}DyK _Toc124828212}DyK _Toc124828213}DyK _Toc124828213}DyK _Toc124828214}DyK _Toc124828214}DyK _Toc124828215}DyK _Toc124828215}DyK _Toc124828216}DyK _Toc124828216}DyK _Toc124828217}DyK _Toc124828217}DyK _Toc124828218}DyK _Toc124828218}DyK _Toc124828219}DyK _Toc124828219}DyK _Toc124828220}DyK _Toc124828220}DyK _Toc124828221}DyK _Toc124828221}DyK _Toc124828222$$If!vh#v":V l ` t 065"` p :$$If!vh#vL:V l t65L$$If!vh#v":V l ` t 065"` p $$If!vh#vP:V l ` 065P4` p $$If!vh#vP:V l ` 065P4` p $$If!vh#vP:V l ` 065P4` p $$If!vh#vP:V l ` 065P4` p $$If!vh#vP:V l ` 065P4` p $$If!vh#vP:V l ` 065P4` p $$If!vh#vP:V l ` 065P4` p $$If!vh#vP:V l ` 065P4` p $$If!vh#vP:V l ` 065P4` p $$If!vh#v(:V l| ` 065(4` p $$If!vh#v(:V l ` t 065(` p $$If!vh#v(:V l ` t 065(` p $$If!vh#v":V l ` t 065(` p DyK www.dhp.virginia.gov/pharmacyyK Jhttp://www.dhp.virginia.gov/pharmacy$$If!vh#v":V l ` t 065(` p @$$If!vh#vL:V l t65yt J@$$If!vh#vL:V l t65yt J@$$If!vh#vL:V l t65yt J@$$If!vh#vL:V l t65yt J@$$If!vh#vL:V l t65yt J@$$If!vh#vL:V l t65yt J$$Ifx!vh#vH:V x$5H/ / /  / 4 xaxytz{$$Ifx!vh#vH:V x$5H/ / / / 4 xaxytz{$$Ifx!vh#vH:V x$5H/ / / / 4 xaxytz{$$Ifx!vh#vH:V x$5H/ / / / 4 xaxytz{$$Ifx!vh#vH:V x$5H/ / / / 4 xaxytz{$$Ifx!vh#vH:V x$5H/ / / / 4 xaxytz{$$Ifx!vh#vH:V x$5H/ / / / 4 xaxytz{$$Ifx!vh#vH:V x$5H/ / / / 4 xaxytz{$$Ifx!vh#vH:V x$5H/ / / / / 4 xaxytz{$$Ifx!vh#vH:V x$5H/ / / / / 4 xaxytz{$$Ifx!vh#vH:V x$5H/ / / / 4 xaxytz{$$Ifx!vh#vH:V x$5H/ / / / 4 xaxytz{$$Ifx!vh#vH:V x$5H/ / / / 4 xaxytz{$$Ifx!vh#vH:V x$5H/ / / / 4 xaxytz{$$Ifx!vh#vH:V x$5H/ / / / 4 xaxytz{$$Ifx!vh#vH:V x$5H/ / / / 4 xaxytz{$$Ifx!vh#vH:V x$5H/ / / / 4 xaxytz{$$Ifx!vh#vH:V x$5H/ / / / 4 xaxytz{$$Ifx!vh#vH:V x$5H/ / / / 4 xaxytz{$$Ifx!vh#vH:V x$5H/ / / / / 4 xaxytz{$$Ifx!vh#vH:V x$5H/ / / / /  4 xaxytz{$$Ifx!vh#vH:V x$5H/ / /  / 4 xaxyt"$$Ifx!vh#vH:V x$5H/ / / / 4 xaxyt"$$Ifx!vh#vH:V x$5H/ / / / 4 xaxyt"$$Ifx!vh#vH:V x$5H/ / / / 4 xaxyt"$$Ifx!vh#vH:V x$5H/ / / / 4 xaxyt"$$Ifx!vh#vH:V x$5H/ / / / 4 xaxyt"$$Ifx!vh#vH:V x$5H/ / / / 4 xaxyt"$$Ifx!vh#vH:V x$5H/ / / / 4 xaxyt"$$Ifx!vh#vH:V x$5H/ / / / 4 xaxyt"$$Ifx!vh#vH:V x$5H/ / / / 4 xaxyt"$$Ifx!vh#vH:V x$5H/ / / / / 4 xaxyt"$$Ifx!vh#vH:V x$5H/ / / / /  4 xaxyt"}$$Ifx!vh#vH:V x5H/ / /  / 4 xaxyt J}$$Ifx!vh#vH:V x5H/ / / / 4 xaxyt J}$$Ifx!vh#vH:V x5H/ / / / 4 xaxyt J}$$Ifx!vh#vH:V x5H/ / / / 4 xaxyt J}$$Ifx!vh#vH:V x5H/ / / / 4 xaxyt J}$$Ifx!vh#vH:V x5H/ / / / 4 xaxyt J}$$Ifx!vh#vH:V x5H/ / / / 4 xaxyt J}$$Ifx!vh#vH:V x5H/ / / / 4 xaxyt J}$$Ifx!vh#vH:V x5H/ / / / 4 xaxyt J}$$Ifx!vh#vH:V x5H/ / / / 4 xaxyt J}$$Ifx!vh#vH:V x5H/ / / / 4 xaxyt J}$$Ifx!vh#vH:V x5H/ / / / 4 xaxyt J}$$Ifx!vh#vH:V x5H/ / / / 4 xaxyt J$$Ifx!vh#vH:V x5H/ / / / / 4 xaxyt J$$Ifx!vh#vH:V x5H/ / / / / 4 xaxyt J}$$Ifx!vh#vH:V x5H/ / / / 4 xaxyt J}$$Ifx!vh#vH:V x5H/ / / / 4 xaxyt J}$$Ifx!vh#vH:V x5H/ / / / 4 xaxyt J}$$Ifx!vh#vH:V x5H/ / / / 4 xaxyt J$$Ifx!vh#vH:V x5H/ / / / / 4 xaxyt"$$Ifx!vh#vH:V x5H/ / / / /  4 xaxyt"}$$Ifx!vh#vH:V x5H/ / /  / 4 xaxyt J}$$Ifx!vh#vH:V x5H/ / / / 4 xaxyt J$$Ifx!vh#vH:V x5H/ / / / /  4 xaxyt J$$If!vh#vL:V l t 6`5065Lyt J$$If!vh#vL:V l t 6`5065Lyt J$$If!vh#vL:V l t 6`5065Lyt J$$If!vh#vL:V l t 6`5065Lyt J$$If!vh#vL:V l t 6`5065Lyt J$$If!vh#vL:V l t 6`5065Lyt J^# h2 0@P`p2( 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p8XV~_HmH nH sH tH B`B Normal$a$CJ_HmH sH tH T@T  Heading 1$$<@&a$5;@CJKH@@@  Heading 2$<@&5<<  Heading 3$<@&<<  Heading 4$<@&>@>  Heading 6 <@&CJ>@>  Heading 7 <@&CJ>@>  Heading 8 <@&CJ> @>  Heading 9 <@&CJDA`D Default Paragraph FontVi@V  Table Normal :V 44 la (k (No List LOL Application form5CJOJQJD@D Header  !5CJOJQJ8 @8 Footer5CJOJQJ6U`!6 Hyperlink >*B*phLP@2L Body Text 2$a$CJOJQJ^JaJ0B0 Style1 XRX HEADING 1 BEFORE 0 AFTER 0 6>@b6 Title$a$ 5\aJdOrd Outline 1,$ 0X h*$^h`a$ 5@CJ`O` Outline 2,$ 0*$^`a$@CJ@@ Outline 3 p8^8BB Outline 4 p^66 Outline 5 ^.)@. Page Number8@8 TOC 2$^a$aJ*W`* 5`Strong5\FV`F <FollowedHyperlink >*B*phD@D 4 List Paragraph ^m$H@H "z{ Balloon Text!CJOJQJ^JaJNo!N !z{Balloon Text CharCJOJQJ^JaJPK![Content_Types].xmlN0EH-J@%ǎǢ|ș$زULTB l,3;rØJB+$G]7O٭V$ !)O^rC$y@/yH*񄴽)޵߻UDb`}"qۋJחX^)I`nEp)liV[]1M<OP6r=zgbIguSebORD۫qu gZo~ٺlAplxpT0+[}`jzAV2Fi@qv֬5\|ʜ̭NleXdsjcs7f W+Ն7`g ȘJj|h(KD- dXiJ؇(x$( :;˹! I_TS 1?E??ZBΪmU/?~xY'y5g&΋/ɋ>GMGeD3Vq%'#q$8K)fw9:ĵ x}rxwr:\TZaG*y8IjbRc|XŻǿI u3KGnD1NIBs RuK>V.EL+M2#'fi ~V vl{u8zH *:(W☕ ~JTe\O*tHGHY}KNP*ݾ˦TѼ9/#A7qZ$*c?qUnwN%Oi4 =3N)cbJ uV4(Tn 7_?m-ٛ{UBwznʜ"Z xJZp; {/<P;,)''KQk5qpN8KGbe Sd̛\17 pa>SR! 3K4'+rzQ TTIIvt]Kc⫲K#v5+|D~O@%\w_nN[L9KqgVhn R!y+Un;*&/HrT >>\ t=.Tġ S; Z~!P9giCڧ!# B,;X=ۻ,I2UWV9$lk=Aj;{AP79|s*Y;̠[MCۿhf]o{oY=1kyVV5E8Vk+֜\80X4D)!!?*|fv u"xA@T_q64)kڬuV7 t '%;i9s9x,ڎ-45xd8?ǘd/Y|t &LILJ`& -Gt/PK! ѐ'theme/theme/_rels/themeManager.xml.relsM 0wooӺ&݈Э5 6?$Q ,.aic21h:qm@RN;d`o7gK(M&$R(.1r'JЊT8V"AȻHu}|$b{P8g/]QAsم(#L[PK-![Content_Types].xmlPK-!֧6 0_rels/.relsPK-!kytheme/theme/themeManager.xmlPK-!0C)theme/theme/theme1.xmlPK-! ѐ' theme/theme/_rels/themeManager.xml.relsPK] O|ORr$'')(|J}JJK>MzNO (*,,,,,,,,,,:::::::::::::::::::::::::::=T - y  Mn,1QnJsxw|CFGHIJLMNOPVX[chot(6 T;!}"<#$&,,I,,//802$6M;CJrNU]?e[kn]oop6qqqqr,r^rrrIss7ttuQuuu v0v\v~vvvvwVwwww+x{{{{|||DEKQRSTUWYZ\]^_`abdefgijklmnpqrsuvwxyz{|}~=RSs}4PRSUu.013Sk1346V^z|}:Wsuvx "#%Eh2NPQSs&)XrW((((<)))*K*w*xrxz/{w{| tX%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X̕XXXXXXX"$-47=!!t!@ @H 0(  x(  t  c $#" `? b  3 #" `? B S  ?|SL&tT$t _Hlt245802114 _Hlt245802115 _Hlt124828223 _Hlt124828224 _Hlt240784935 _Hlt240784936 _Toc124828204 _Toc124828205 _Toc124828206 _Toc124828207 _Toc124828208 _Toc124828209 _Toc124828210 _Toc124828211 _Toc124828212 _Toc124828213 _Toc124828214 _Toc124828215 _Toc124828216 _Toc124828217 _Toc124828218 _Toc124828219 _Toc124828220_GoBack _Toc124828221 _Toc124828222##]]T v/I$$'*(O*75cc|@@@@@@ $$^^o 8|;^$$'7(*75c(t|IIIIIIIIIIIIIIIIIIIIIIIIIIIIII$$L%L%%%&&l&l&NNccffgg,t,tz|         $$T%T%%%&&t&t&NNccff"g"g0t0tz|  B*urn:schemas-microsoft-com:office:smarttagscountry-region>*urn:schemas-microsoft-com:office:smarttags PersonName8*urn:schemas-microsoft-com:office:smarttagsCity9*urn:schemas-microsoft-com:office:smarttagsplace>*urn:schemas-microsoft-com:office:smarttags PostalCode9*urn:schemas-microsoft-com:office:smarttagsState=*urn:schemas-microsoft-com:office:smarttags PlaceName=*urn:schemas-microsoft-com:office:smarttags PlaceType;*urn:schemas-microsoft-com:office:smarttagsaddress:*urn:schemas-microsoft-com:office:smarttagsStreet [j &&''F'I'hPwP#i-iMiSiUi\i|iiiiiiiiiiijjjjjRj]j_jpj|jjjjjj kkk kBkHkVk_kakhkjkpkwk}kkkkkkkll\lcl}llllllllllm'm(m.m0m?m@mGmRm\m]memgmpmrmmmmmmmmmmmmmmmmmmmmCnSn]nenfnknmnunvn}nnnnnnnnnnnnnnnnnnnoooo(D J~bTecgjglhz{}-coi=`-4Wd5r]lpGg~+E \h!Na<w/L(`z{|{@ffff|@Unknown G*Ax Times New Roman5Symbol3. *Cx ArialY CG TimesTimes New RomanA. Arial Narrow5. .[`)Tahoma;Wingdings?= * Courier NewA$BCambria Math"qhƒ6GŃ6Gm i?m i?q24;{;{2QX ?}6!xx 0         Oh+'0   $, Normal.dotm1Microsoft Office Word@@Dff@Wgm iOtudy Guide (Examination Handbook) for Virginia Federal and State Drug Law Exam՜.+,D՜.+, `hpx  ?;{  Title  8@ _PID_HLINKSA rLHhttp://www.deadiversion.usdoj.gov/pubs/manuals/pharm2/pharm_content.htm7cHhttp://www.gpo.gov/fdsys/browse/collectionCfr.action?collectionCode=CFR7c~Hhttp://www.gpo.gov/fdsys/browse/collectionCfr.action?collectionCode=CFRA{Nhttp://www.gpo.gov/fdsys/browse/collectionUScode.action?collectionCode=USCODEWx%http://www.dhp.virginia.gov/pharmacyGu"http://www.isoqualitytesting.com/wrChttps://www.iqttesting.com/Default.aspx?Function=SampleExam&Exam=85n_Toc1248282225h_Toc1248282215b_Toc1248282205\_Toc1248282195V_Toc1248282185P_Toc1248282175J_Toc1248282165D_Toc1248282155>_Toc12482821458_Toc12482821352_Toc1248282125,_Toc1248282115&_Toc1248282105 _Toc1248282095_Toc1248282085_Toc1248282075_Toc1248282065_Toc1248282055_Toc124828204  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !+,-./0169Root Entry F`H8@Data >1TableXWordDocumentPSummaryInformation(DocumentSummaryInformation8*CompObjr  F Microsoft Word 97-2003 Document MSWordDocWord.Document.89qOh+'0   $,DHP Normal.dotm1Microsoft Office Word@@Dff@Wgm iOtudy Guide (Examination Handbook) for Virginia Federal and State Drug Law Exam